参考文献/References:
[1]李文萍,王颀,张安秦,等.乳腺导管内癌及伴微浸润的病理和临床特征.中华普通外科杂志,2005,20:235-237.
[2]汪勇,蔡秀军.乳腺导管内癌的诊治与预后.浙江医学,2003,25:345-346.
[3]孟刚,王保太,杨枫等.小叶-导管复合型癌的病理形态学观察及组织发生学探讨.临床与实验病理学杂志,1998,14(1):13-15.
[4]刘彤华,主编.诊断病理学.北京:人民卫生出版社,1994.577.
[5]高钟禹.乳腺原位癌的起源和发展.临床与实验病理学杂志,1999,15(2):102-104.
[6]左文述,路平华,于金明.乳腺导管内癌及小叶原位癌的治疗策略.中国肿瘤临床,2002,29:376-380.
[7]李万浪,李伟强.乳腺导管内癌的治疗现状.广西医学,2003,25:1453-1457.
[8]李程.乳腺导管内癌的诊治进展.临床外科杂志,2005,13:319-320.
[9]韦佳明,刘治滨.乳腺导管内癌的腋窝淋巴结转移率与术式选择.中国癌症杂志,2004,14:472-473.
[10]林志武,陈晓耕.乳腺导管内癌32例临床分析.福建医科大学学报,2002,36(1):91-92.
[11]Louise B, Eileen R, David M, et al. A Comparison of Four Treatment Strategies for Ductal Carcinoma In Situ Using Decision Analysis. Cancer,2001, 92(1):23-29.
[12]Sakorafas GH, Tsiotou AG. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives. Cancer Treat Rev, 2000, 26(2): 103-125.
[13]Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet, 1999,353:1993-2000.